This study dissected the complexity of the immune architecture of acute myeloid leukemia (AML) at high resolution and assessed its influence on therapeutic response. Using 387 primary bone marrow samples from three discovery cohorts of children and adults with AML, we defined immune-infiltrated and immune-depleted disease subtypes and unraveled critical differences in immune gene expression across age groups and disease stages. Importantly, interferon (IFN)-γ-related mRNA profiles were predictive for both chemotherapy resistance and response of primary refractory/relapsed AML to flotetuzumab immunotherapy. Our compendium of microenvironmental gene and protein profiles sheds novel insights into the immuno-biology of AML and will inform the delivery of personalized immunotherapies to IFNγ-dominant AML subtypes.
measure of IFN-γ-responsive genes that are related to adaptive immune resistance (AIR) mechanisms of immune escape such as indoleamine 2,3-dioxygenase-1 (IDO1) and PD-L1 17 , and is predictive of clinical benefit with pembrolizumab immunotherapy 18, 19 . Although IFN-γ plays a critical role in eliciting anti-tumor T-cell activity and enabling tumor rejection, prolonged IFN-γ signaling under conditions of persistent antigen exposure has been shown to activate a PD-L1-independent, STAT1-driven multigenic program which confers resistance to radiotherapy and anti-cytotoxic T-lymphocyte antigen 4 (CTLA- 4) immunotherapy in mouse models of melanoma 20 .
Herein, we used targeted immune gene expression profiling (IGEP) and spatially-resolved multiplexed digital spatial profiling (DSP) for the high-dimensional analysis of the immunological contexture of a broad collection of bone marrow (BM) samples from patients with AML and for the identification of molecular determinants of immunotherapeutic benefit. We reveal unifying immune features and critical differences that define classes and subclasses of TMEs and deliver predictions of chemotherapy resistance, survival and immunotherapy response that are beyond the current capabilities of single molecular markers.
T-cell markers and cytolytic effectors (CD8A, CD8B, GZMB, PRF1), counter-regulatory immune checkpoints and immunotherapy drug targets (IDO1, CTLA4, PD-L1 and BTLA), and molecules involved in antigen processing and presentation (TAP1, TAP2, HLA-A, HLA-B and HLA-C). Conceivably, high T-cell infiltration, MHC expression and PD-L1 levels in the immune-infiltrated AML subtype reflected a pre-existing IFN-γ-driven adaptive immune response which has previously been associated with suppressed anti-tumor immune reactivity 13, 26 , but also with immunotherapy responses in patients with solid tumors 9, 18, 27 and AML 11 . The expression of STAT1, a central component of the IFN-γ signaling pathway and predictor of response to immune checkpoint blockade 28 , was more strongly correlated with the presence of T-cell inhibitory receptors TNFRSF14 (a ligand for the immunoglobulin superfamily members BTLA and CD160), PD-L1, HAVCR2 (Tim-3) and LAG-3, and with IFN-stimulated genes MX1, IFIT1 and IRF1 in the immune-infiltrated relative to the immunedepleted subtype, consistent with their coordinated regulation in an inflamed TME (Fig. 1D) .
Finally, PD-L1, IFN-γ signaling, IFN downstream signaling and immunoproteasome mRNA scores in the IFN-dominant gene module, but not adaptive and myeloid gene modules (data not shown), individually separated patients into subgroups with different survival probabilities (Extended Data Fig. 1E ).
Highly multiplexed digital spatial profiling (DSP) unravels distinct T-cell neighbors in
immune-infiltrated and immune-depleted AML. Transcriptomic data do not provide information on spatial relationships of tumor-infiltrating immune cells within the TME.
Therefore, we used GeoMx ® DSP to characterize the expression of 31 immuno-oncology (IO) proteins in 10 fresh frozen paraffin embedded (FFPE) BM biopsies from treatment-naïve patients with AML (SAL patient series) with varying degrees of T-cell infiltration (Extended Data Fig. 2A) . We selected 24 geometric regions of interest (ROIs) per BM sample using fluorescent anti-CD3 (visualization marker for T cell-rich ROIs) and anti-CD123 antibodies (visualization marker for myeloid blast-rich ROIs) 29 (Extended Data Fig. 3-4) . T-cell gene expression scores (calculated as detailed in Extended Data Fig. 2B ) correlated with DSP CD3 protein status ( Fig. 2A and Extended Data Fig. 2C ). Furthermore, mRNA and protein levels for B cells, monocytes and Bcl-2 significantly and positively correlated, serving as a validation for the mRNA-based immune scores (Extended Data Fig. 2D ).
We then asked whether CD3-rich and CD3-poor BM samples (defined by a median split of barcode counts) differed in terms of co-localization patterns of relevant IO proteins. As shown in Extended Data Fig. 2A , CD3 + T cells in immune-infiltrated biopsies co-localized with B cells, antigen processing and presentation-related proteins (β2-microglobulin), negative immune checkpoint B7-H3 and β-catenin. In contrast, CD3 + T cells in immunedepleted biopsies co-localized with markers of immunological memory (CD45RO) and T-cell exhaustion (PD-1). When analyzing overall protein expression patterns (10 samples × 24 ROIs per sample × 31 proteins = 7,440 data points), we identified four protein signatures (SIG), which were then further assessed in silico for correlations with clinical-biological disease characteristics and potential prognostic value in The Cancer Genome Atlas (TCGA)-AML cases (162 sequenced AML samples with putative copy-number alterations, mutations and mRNA expression z-scores [threshold±2.0]). Abnormalities in SIG1, SIG2 and SIG4 genes (blue boxes in Fig. 2B ) did not correlate with specific disease characteristics or clinical outcomes (data not shown). In contrast, mRNA up-regulation, gene amplification, deep deletion and mis-sense mutations in SIG3 genes, which were detected in 26% of TCGA-AML cases (Fig. 2C) , significantly correlated with TP53 mutation status, an established adverse prognosticator in AML (p value from mutation enrichment analysis = 0.0285). Alterations in SIG3 genes, which included PD-L1, FoxP3, molecules associated with cell cytotoxicity, PTEN and BCL2, were predominantly observed in patients with immune-infiltrated mRNA profiles ( Fig. 2D) and also correlated with higher number of mutations (median=12 and 9 in AML cases with [n=41] or without [n=115] abnormalities in SIG3 genes, respectively; p=0.021) and with adverse ELN cytogenetic features (χ 2 =25.03; p<0.001), but not with other disease characteristics at presentation, including white blood cell (WBC) count, and percentage of AML blasts in pre-treatment blood and BM samples (data not shown). Finally, patients with abnormalities in SIG3 genes experienced poor clinical outcomes, as shown by the significantly lower RFS and OS rates ( Fig. 2E) .
Collectively, highly multiplexed in situ detection of IO proteins highlights critical differences in T-cell infiltrated versus T-cell depleted AML subtypes and identifies protein signatures with prognostic potential in T-cell infiltrated pre-treatment samples. 5D ). Finally, patients with high immune infiltration tended to be of a more advanced age at diagnosis (median=58 years, range 23-79) compared with patients with low immune infiltration (median=50 years, range 18-63, p<0.0001; Extended Data Fig. 5E ).
Interactions between immune subgroups, common cytogenetic alterations

Immune subtypes improve survival prediction. The activation of immune pathways has
context-dependent prognostic impact that differs between tumor types 6 . We first assessed the ability of the immune subtype to refine the accuracy of outcome prediction separately for each ELN cytogenetic risk category. Among patients with favorable risk, RFS and OS times were significantly longer in individuals with an immune-infiltrated TME (Fig. 3A) . In contrast, clinical outcomes in ELN adverse risk cases were worse in individuals with an immuneinfiltrated TME. We also observed that the ELN classifier assisted outcome prediction only in the immune-infiltrated subtype (Fig. 3B) , allowing the identification of patient subgroups with excellent survival estimates (87.5% RFS and 77.8% OS) or with very unsatisfactory outcomes [10.4% RFS (log-rank χ 2 =15.07; p<0.0001) and 7.2% OS (log-rank χ 2 =25.75; p<0.0001); Fig. 3B ]. This finding is congruent with previous studies showing that specific gene expression profiles correlate with longer OS in patients with favorable-risk AML, but not in those with intermediate-risk or high-risk AML 30 . Similarly, leukemia stem cell-associated gene signatures have been shown to provide prognostic separation within specific ELN risk categories 31 .
Unexpectedly, our immunological classifier was unable to stratify survival in patients with intermediate ELN risk (Fig. 3A) . We therefore employed an immune gene signature-agnostic approach to identify gene sets with prognostic impact in this specific patient category. By performing Cox proportional hazards regression, we discovered a set of 21 differentially expressed (DE) immune genes [false discovery rate (FDR)<0.05] between favorable and adverse-risk AML ( Supplemental Table 1 ), which were significantly associated with OS and exhibited enrichment of gene ontologies (GO) and pathways related to T-cell activation, TCR downstream signaling and regulation of cytokine production ( Fig. 3C) . Interestingly, patients with intermediate-risk AML could be separated into subgroups with low and high gene expression values, with the former being closely similar to ELN favorable-risk patients while the latter resembled ELN adverse-risk patients (Fig. 3D) . Importantly, RFS and OS estimates were significantly poorer for intermediate-risk patients with high versus low expression levels of the 21 DE genes ( Fig. 3E ).
Immune landscapes stratify AML patients in independent validation sets and differ
across age groups and disease stages. AML is a disease with age-dependent biological specificities 32,33 . Furthermore, pediatric AML are inherently of low immunogenicity and are therefore less likely to respond to single-agent checkpoint inhibition 34 . To characterize the immunological landscape of AML across age groups and longitudinally in patients who initially achieve complete remission (CR) and then experience disease recurrence, we profiled BM samples from a pediatric (CHOP series, n=39 cases) and an adult AML cohort (SAL series, n=38 cases, 58 BM specimens in total). In line with findings in the PMCC discovery series, we identified IFN-dominant, adaptive and myeloid mRNA profiles Fig. 7C ), we identified a set of DE genes (FDR<5.72×10 -4 ) that were enriched for GO biological processes related to the innate immune response, cytokine signaling and toll-like receptor (TLR) cascade (Supplemental Table 3 ). As shown in Fig. 8C ). The DE genes between patient subgroups with newly diagnosed, CR and relapsed AML in the SAL cohort, and between childhood and adult cases, were largely nonoverlapping, as shown in Extended Data Fig. 7E . IFN-related gene sets improve the prediction of therapy resistance. We then asked whether the IFN-dominant gene module herein computed as the sum of IFN-γ signaling, IFN downstream, immunoproteasome, myeloid inflammation, inflammatory chemokine, IL-10, MAGE, PD-L1 and PD-L2 scores ( Fig. 1 and Extended Data Fig. 1C ) may assist the prediction of therapeutic resistance, which we empirically defined as failure to achieve CR in patients who survived at least 28 days (primary refractory AML) or as early relapse (<3 months) after achieving CR, as previously published by others 37 . When AML patients in the PMCC cohort were dichotomized based on higher or lower than median IFN scores, a higher percentage of patients with primary refractory disease was observed in the IFN-score high AML cases (65.4% versus 34.6%; p=0.0022, Fisher's exact test), suggesting that transcriptional programs orchestrated by microenvironmental IFN-γ might render AML blasts resistant to chemotherapeutic agents 20,38 . In contrast, the frequency of primary refractory cases was not different when comparing AML patients with higher or lower than median adaptive module scores (29.6% versus 25.4%; p=NS) and myeloid module scores (26.7% versus 28.1%; p=NS). In multivariate logistic regression analysis, the IFN-related module scores significantly improved the ability of the ELN category to predict therapeutic resistance ( Fig. 4A-B ; AUROC = 0.815 versus 0.702 with ELN risk only; model χ 2 =65.87 versus 33.43; increased sensitivity compared to ENL risk only=15.6%; increased specificity=3%; decreased false positive rate=11.5%; decreased false negative rate=4.9%), but not patient survival (data not shown). Specifically, the myeloid inflammation score (p=0.003), IFN-γ signaling score (p=0.014) and IFN downstream score (p=0.034) significantly contributed to the model (Supplemental Table 5 ). Gene sets defining gene modules 2 and 3 in Fig. 1 , reflective of adaptive immune responses and BM infiltration with cells of the myeloid lineage, respectively, were not associated with either therapeutic resistance or patient survival (data not shown).
In silico validation of therapy prediction by immune subtypes in the Beat AML and HOVON cohorts. We next tested the predictive and prognostic power of immune scores in silico using a broad collection of public transcriptomic data. We initially devised binary logistic regression models utilizing RNA-sequencing data from 196 patients on the Beat AML Master Trial ® with clinical response information 39 . When considering disease type (primary versus secondary), WBC count and patient age at diagnosis, the inclusion of genes capturing IFN-γ-related biology significantly improved the predictive ability of the ELN risk category (AUROC=0.921 versus 0.709 with ELN cytogenetic risk alone; model χ 2 =106.4 versus 29.6; increased specificity=4%; increased sensitivity=17%; decreased false positive rate=39%; decreased false negative rate=18%; Fig. 4C ).
Confirming our findings in the PMCC and Beat AML ® cohorts, IFN-dominant, adaptive and myeloid mRNA profiles, when used in aggregate, stratified patients in the HOVON database (618 non-promyelocytic AML cases 40 ) into subgroups with high and low immune infiltration ( Fig. 4D-E) . Individuals with immune-infiltrated AML had lower leukemia burden (median percentage of BM blasts=56% versus 71% in patients with immune-depleted AML; p<0.0001) and tended to have more advanced age at diagnosis (median=51 years, range 15-74, versus 46 years, range 15-77; p=0.0067). A higher percentage of patients with IFNdominant AML failed to achieve CR in response to induction chemotherapy when compared to non-IFN-dominant AML cases (27.2% versus 15.2%; p=0.0004, Fisher's exact test). In contrast, the occurrence of induction failure (IF) was not different when patients were dichotomized based on higher or lower than median adaptive module scores (21.4% versus 21.0% IF rate; p=NS) or myeloid module scores (21.7% versus 20.7% IF rate; p=NS). Gene set enrichment analysis (GSEA) with all transcripts in the HOVON dataset provided as input and ranked by the log 2 fold-change between non-responders and responders confirmed the over-expression of curated hallmark gene sets linked to IFN-γ responses and inflammatory responses in chemotherapy-refractory patients ( Fig. 4F ; Supplemental Table 6 ). When tested in a multinomial logistic regression model incorporating patient age, leukemia burden and ELN cytogenetic risk (available in 615 HOVON cases) 41 , immune gene sets defining the IFN-dominant module significantly and independently predicted whether patients responded to induction chemotherapy and whether they experienced disease relapse (Supplemental Table 7 ). In contrast, immune gene signatures were unable to assist the prediction of nonleukemic deaths (Supplemental Table 7 ).
Mutations in tumor suppressor genes and transcription factors are enriched in
immune-infiltrated AML cases. It has recently been shown that genetic drivers of solid malignancies dictate neutrophil and T-cell recruitment, thus affecting the immune milieu of the tumor and assisting patient stratification 42 . We asked whether clonal driver mutations may correlate with the immune subtypes that we identified herein. We therefore retrieved TCGA AML RNA-sequencing data from cBioPortal (http://www.cbioportal.org/) and computed immune cell type-specific and biological activity scores 22 . The mutational spectrum of TCGA-AML cases, including co-occurrence and exclusivity of the most frequent molecular lesions, is shown in Extended Data Fig. 9 . Mis-sense mutations, mRNA upregulation, deep deletion and amplification in IFN downstream genes are summarized in Extended Data Fig. 10 . Patients with adverse-risk molecular lesions, including somatic TP53 mutations and RUNX1 mutations, clustered in the immune-infiltrated subgroup (Extended Data Fig. 10A ). In particular, IFN-related gene sets, including the tumor inflammation signature (TIS) score, were expressed at significantly higher levels in TCGA-AML cases with TP53 and RUNX1 mutations relative to molecular lesions that confer favorable or intermediate risk (Extended Data Fig. 11A-B) . In contrast, the majority of TCGA-AML cases with NPM1 mutations with or without FLT3-ITD (intermediate-risk and favorable-risk cases, respectively) were classified as immune-depleted. When extending our in-silico analysis to the Beat AML ® cohort (281 cases in total), 16 out of 17 (94%) TP53mutated AMLs expressed higher levels of genes implicated in downstream IFN signaling and higher levels of CD8 transcripts and markers of cytotoxicity compared with TP53 wild-type cases (Extended Data Fig. 11C-D) . were profiled using the PanCancer IO360™ gene expression assay. Patients' characteristics are summarized in Supplemental Table 8 . BM samples from 92% of patients with evidence of FLZ anti-leukemic activity (11 out of 12), which was defined as either CR, CR with partial hematologic recovery (CRh), CR with incomplete hematologic recovery (CRi), partial response or overall benefit (>30% reduction in BM and/or blood blasts), had an immuneinfiltrated TME relative to non-responders ( Fig. 5A) . Interestingly, the IFN-dominant module score was significantly higher in patients with chemotherapy-refractory AML compared with relapsed AML at time of FLZ treatment, and in individuals with evidence of anti-leukemic activity compared to non-responders ( Fig. 5B) . Notably, the TIS score was a stronger predictor of anti-leukemic responses to FLZ, with an AUROC value of 0.847 ( Fig. 5B) . Ontreatment BM samples (available in 19 patients at the end of cycle 1) displayed increased antigen presentation and immune activation relative to baseline samples, as reflected by higher TIS scores (6.47±0.22 versus 5.93±0.15, p=0.0006), antigen processing machinery scores (5.67±0.16 versus 5.31±0.12, p=0.002), IFN-γ signaling scores (3.58±0.27 versus 2.81±0.24, p=0.0004) and PD-L1 expression (3.43±0.28 versus 2.73±0.21, p=0.0062; Fig.   5C ). Overall, these data substantiate a clinical benefit for AML patients with an immuneinfiltrated TME, support a local immune-modulatory effect of FLZ treatment and validate the translational relevance of our findings.
IFN-γ-related gene expression profiles correlate with anti-leukemia responses
Discussion
Using large cohorts of subjects, the current study is the first to reveal underlying transcriptomic features that stratify the TME of AML into immune subtypes and may assist therapeutic predictions by defining patients who will potentially derive the greatest benefit from immunotherapies 11, 46 . We identified two subtypes of differentially-infiltrated tumors, an observation that was validated in independent childhood and adult AML series, reinforcing the notion that unique molecular features can distinguish AML across age groups 33 
Methods
Methods, including statements of data availability and any associated accession codes and references, are available online. 
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Online Methods
Patients' demographics (discovery cohorts). Patient and disease characteristics are detailed in Table 1 . RNA isolation and processing.
Messenger RNA was isolated and processed as previously described 41 Table 9 ).
Stained slides were loaded on the DSP instrument and digitally scanned. Fluorescent scans were used to select 24 geometric regions of interest (ROIs) 27, 59 . The DSP instrument then UV-illuminated selected ROIs to release conjugated oligos and the micro-capillary fluidics system collected released oligos, which were counted on the nCounter system.
Data sources for in silico analyses. The first data series (E-MTAB-3444), hereafter referred to as the HOVON series 40 Subjects lost to follow-up were censored at their date of last known contact.
Binary logistic regression and multinomial logistic regression were used to ascertain the relative contribution of immune subtypes and other pretreatment covariates selected a priori based on known clinical relevance (ELN risk group, FLT3-ITD status, NPM1 mutational status, patient age at diagnosis and primary versus secondary AML) toward the predicted likelihood of response to induction chemotherapy, AML relapse and patient death 41 .
Variables measured after the initiation of induction chemotherapy were excluded, since the goal of the current study was to identify AML patients at higher risk of treatment failure prior to starting therapy.
Data availability. Gene expression data have been deposited in NCBI's Gene Expression
Omnibus 62 and are accessible through GEO Series accession number GSE134589 Supplemental Table 6 . Each run was performed with 1,000 permutations. FDR=false discovery rate. Fig. 3 
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